CYTK vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 14, 2026
CYTK
MRNA
Investment Advisor Scores
MRNA
AI Analyst Insights
Detailed Metrics Comparison
| Metric | CYTK | MRNA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 117.6471 | 23.0415 | MRNA |
| PEG Ratio | -0.42 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | -57.1% | 2.1% | MRNA |
| Earnings Growth | 0.0% | -85.1% | CYTK |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 55.8/100 | 42.9/100 | CYTK |
| Profit Margin | 0.0% | -141.4% | CYTK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
CYTK
NeutralMixed signals - no dominant trend phase, RSI 47
MRNA
MarkupPrice above SMA50, rising 50-day trend (17.2% over 20 days), RSI 72
Fundamentals Snapshot
| Metric | CYTK | MRNA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -17.3 | -29.8 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | -0.6% | 0.0% |
| Gross Margin | -5.0% | -0.7% |
| Operating Margin | -6.3% | -5.6% |
| EPS | -7.18 | -6.11 |
| Dividend Yield | — | — |